Castleman’s disease in the rheumatological practice
Schmalzing M, Sander O, Seidl M, et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024 Aug 22;83(3). doi:10.1007/s00393-024-01560-5
Schmalzing M, Sander O, Seidl M, et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024 Aug 22;83(3). doi:10.1007/s00393-024-01560-5
EGFR, non small cell lung cancer (NSCLC), tyrosine kinase inhibitor (TKI)
Christopoulos P, Herster F, Hoffknecht P, Falk M, Tiemann M, Kopp HG, et al. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report. Front Oncol 2024 May 06;14:1347742. doi: 10.3389/fonc.2024.1347742
disease monitoring, EGFR, hybrid capture-based next-generation sequencing (NGS), Liquid Biopsy, Osimertinib
Falk M, Schatz S, Reich FPM, Schmidt S, Galster M, Tiemann M, et al. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Curr. Oncol. 2023 Sep 28;30(10):8865-8871. doi:10.3390/curroncol30100640
NOGGO GIS v1 Assay
Willing EM, Vollbrecht C, Vössing C, et al. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers 2023 Jun 30;15(13):3445. doi:10.3390/cancers15133445
Barrett’s esophagus, Barrett’s Oesophagus, carcinogenesis, dysplasia, Dysplasie, esophageal adenocarcinoma, Inflammatorische Signalwege, inflammatory signaling pathways, intestinal metaplasia, Intestinale Metaplasie, Karzinogenese, mutational load, Mutationslast, oesophageales Adenokarzinom, p53
Maslenkina K, et al. Signaling Pathways in the Pathogenesis of Barrett’s Esophagus and Esophageal Adenocarcinoma. Int J Mol Sci 2023 May 26;24(11):9304. doi:10.3390/ijms24119304
Brandwunde, burn wound, fibröse extrazelluläre Matrix, fibrous extracellular matrix, Haut, Mast cells, Mastzellen, molecular hydrogen, molekularer Wasserstoff, Regeneration, Skin
Atiakshin D, et al. Mast Cells in Regeneration of the Skin in Burn Wound with Special Emphasis on Molecular Hydrogen Effect. Pharmaceuticals (Basel) 2023 Feb 24;16(3):348. doi:10.3390/ph16030348
disease monitoring, HER2 Mutation, Krankheitsmonitoring, Liquid Biopsy, Trastuzumab Deruxtecan
Falk M, et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Curr Oncol 2023 Jan 30;30(2):1692-1698. doi:10.3390/curroncol30020130
